This site is intended for healthcare professionals
Drug news

FDA advisers recommmend CV trial for Vascepa (Amarin)

Read time: 1 mins
Last updated:18th Oct 2013
Published:18th Oct 2013
Source: Pharmawand

Amarin Corporation had submitted a Supplemental New Drug Application (sNDA) with the FDA seeking approval for the marketing and sale of Vascepa (icosapent ethyl) capsules for additional use as an adjunct to diet in the treatment of adult patients with high triglycerides and with Mixed Dyslipidemia (ANCHOR indication).

A panel of advisers to the FDA on 16 October condidered that Amarin should be required to complete its ongoing cardiovascular outcomes trial (REDUCE-IT) before the FDA permits the company to expand the labeling for Vascepa.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.